Nepriklausoma sveikatos laboratorija, MB - company info and details
Company age: 3 y. 4 mo.
Company overview
Basic information
Company name
Nepriklausoma sveikatos laboratorija, MB
Company code
306334999
Registered address
Vilnius, Žirmūnų g. 128-10, LT-09126
Registration date
2023-06-08
Company age: 3 y. 4 mo.
Contact information
Edit data
Phone
Presented as an image – cannot be copied
Presented as an image – cannot be copied
Email
Not disclosed
(personal)
Website
None
Company manager
For registered members only
Log in
Indicators
Risk factors
Activity
Legal form
Small partnership
NACE activity
Activities of advertising agencies
Ownership form
Private without foreign capital
Nepriklausoma sveikatos laboratorija, MB
Company code: 306334999
Address: Vilnius, Žirmūnų g. 128-10, LT-09126
Description
This description was generated by artificial intelligence.
Nepriklausoma sveikatos laboratorija, MB (company code 306334999) is an operational private small partnership registered on 8 June 2023. It is classified as a micro company within the national private non-financial companies sector and operates under CEO-only governance. The company is privately owned, with more than 50% of authorised capital held by Lithuanian natural and legal persons and no foreign investor capital. Its main activity is registered under EVRK code N.73.11.00, Activities of advertising agencies. The company is based in Vilnius, Žirmunu g. 128-10, in Vilnius municipality, Vilnius County. Financially, the company reported revenue of EUR 19.5K in 2023, covering a 206-day period, and EUR 2.4K in 2024. Net profit was negative in both years, at a loss of EUR 1.9K in 2023 and EUR 3.2K in 2024. The profit margin moved from -9.5% to -134.2%. Equity remained negative, while liabilities decreased from EUR 12.3K to EUR 10.2K and total assets declined from EUR 11.0K to EUR 7.5K.
Download a detailed company report
Make confident decisions with all the information about Nepriklausoma sveikatos laboratorija, MB. In one document, you will find full financial data, risk and potential assessment, and key Scoris insights.